GLP-1s shouldnt be viewed as short-term fixes either, the editorial says
Meanwhile, 20% report that they cover GLP-1s for obesity only at a BMI of 35 or more
Key Research Findings & Benefits Unprecedented Weight Loss Data: Clinical trials have demonstrated mean weight reductions of up to 24.2%, approaching bariatric surgery outcomes
Lancet 406 , 149162 (2025)
Issued in the European Economic Area (EEA) by William Blair B.V., authorized and supervised by the Dutch Authority for the Financial Markets (AFM) under license number 14006134 and also supervised by the Dutch Central Bank (DNB), registered at the Dutch Chamber of Commerce under number 82375682 and has its statutory seat in Amsterdam, the Netherlands
Traveling with retatrutide: maintaining the cold chain Travel is where most storage protocols break down